Researchers have been excited about the medication , a innovative dual agonist showing significant outcomes in initial trials for size reduction . It acts by targeting both systems: GLP-1 and GIP, which https://sahilhmzr518385.myparisblog.com/41310666/the-new-possibility-for-body-management